The use of Posaconazole, also known as the brand name Noxafil, continues to be a reliable and effectual therapy for fighting fungal infections. Posaconazole is FDA approved to treat fungal infections occurring in patients with weakened immune systems, like patients with HIV infection or those who are recovering from stem cell transplantation. In March 2014, the Posaconazole 18 mg/ml injection was approved as Noxafil injection, marketed by Merck, as a prophylaxis for invasive Aspergillus and Candida infections in patients ages 13 and older. This adolescent indication was welcomed by this patient population who are in need of efficacious treatment for preventing deadly fungal infections. This novel formulation for intravenous use joined Posaconazole 100 milligram delayed release tablets and 40 milligram oral suspension for the prophylaxis of invasive Aspergillus and Candida infections in patients ages 18 and older. The advent of the Posaconazole (Noxafil) injection offered an appropriate transition to oral Posaconazole treatment for patients, with a small occurrence of adverse effects. Side effects from Posaconazole reported by patients includes diarrhea, nausea and mild fever.
The delayed-release Posaconazole tablets performed exceedingly well in several comparative and multicenter studies. Both the safety and tolerability of Posaconazole was established in a variety of patients. One study involved patients with acute myeloid leukemia or myelodysplastic syndrome and who had developed (or was developing) significant neutropenia. Study participants received a once-daily dose of Posaconazole (Noxafil) delayed-release tablets, following a 300 milligram loading dose on the first day of treatment. Administration of Posaconazole with food increased the oral bioavailability of this potent product, and laboratory data revealed that the delayed-release tablets provided higher plasma drug exposures in comparison to the oral suspension.
However, Posaconazole oral suspension is also clinically effective, as proven with data from two viable studies. The aforementioned studies examined the prophylaxis of Aspergillus type infections in immunocompromised patients. Study participants in these trials were administered for prophylaxis of fungal infections with either Posaconazole, Itraconazole or Fluconazole. The patient group who received Posaconazole were given 200 milligrams of the oral suspension three times daily. This was compared with 400 milligrams of Fluconazole oral suspension once daily or Itraconazole 200 milligram oral suspension twice daily. The successful prevention of invasive fungal infections in these neutropenic patients was the goal of these studies. The clinical failure in patients was lower for the group who received Posaconazole, at 27 percent. In comparison, the patients who were administered Fluconazole and Itraconazole experienced a 42 percent clinical failure rate. As with the intravenous and delayed release tablets, adverse effects were uncommon, and included reports of nausea, diarrhea and vomiting. LGM Pharma can assist clients as a supplier/distributor of the Posaconazole API, CAS # 171228-49-2 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.